US Patent Issued to Origenis on Aug. 12 for "1,4-dihydrobenzo[dpyrazolo[3,4-f[1,3diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease" (German Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,788, issued on Aug. 12, was assigned to Origenis GMBH (Martinsried, Germany).

"1,4-dihydrobenzo[dpyrazolo[3,4-f[1,3diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease" was invented by Roland Koestler (Martinsried, Germany), Jean Tassel (Augsburg, Germany), Michael Thormann (Planegg, Germany), Nasser Yehia (Munich), Andreas Treml (Bodenmais, Germany) and Michael Almstetter (Grasbrunn, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or mor...